NexACT Technology Enhances Rituximab Bioavailability When Administered Subcutaneously: NexMed
The study results showed that animals receiving subcutaneous injections of Rituximab, incorporated with NexACT, demonstrated a 46% enhancement in bioavailability over Rituximab, alone. Rituximab is a cancer medication
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.